1 Can H<sub>2</sub>-receptor upregulation and raised histamine explain an anaphylactoid

# 2 reaction on cessation of ranitidine in a 19 year old female? A case report

- (short running title: 'Anaphylaxis on cessation of ranitidine')
- 4 Susan J Allen<sup>1\*</sup>, C Jane Dixon<sup>2</sup>, Paul L Chazot<sup>2</sup>

Susan J Allen MRPharmS PGDip Senior Lecturer in Pharmacy Practice Leicester School of Pharmacy De Montfort University Hawthorn Building Leicester LE1 9BH Paul L Chazot PhD FBPhS Associate Professor in Pharmacology

2 Department of Biosciences
 Durham University
 South Road
 Durham DH13LE

C Jane Dixon PhD Senior Lecturer in Pharmacology Leicester School of Pharmacy De Montfort University Hawthorn Building Leicester LE1 9BH

- 5 \* Author for correspondence: Susan J Allen, sjallen@dmu.ac.uk
- 6

3

- 7
- 8 The patient was treated at:
- 9 The Minor Injuries Unit, Townlands Memorial Hospital, Henley, Oxon RG9 2DR and transferred for
- 10 observation to: Royal Berkshire Hospital, Reading, Berks RG1 5AN.

11

- 12 Conflict of interest statement
- 13 There are no conflicts of interest with respect any of the authors and the content of this case report.
- 14 [The first author, S. Allen, is a relative of the patient subject of this report.]

15

- 16 Ethics
- 17 This is a retrospective case report of an unpredicted adverse effect following drug withdrawal.
- 18 Informed written consent to obtain hospital results and to publish was obtained from the patient.
- 19 Patient identity is protected and confidentiality observed at every stage.

20

## 21 Summary

22	The anaphylactoid reaction described follows cessation of ranitidine in a 19 year old female with the				
23	disease cluster: mast cell activation syndrome, hypermobile Ehlers-Danlos syndrome and postural				
24	tachycardia syndrome.				
25	Anaphylaxis can give wide-ranging symptoms from rhinorrhoea and urticaria to tachycardia and				
26	system-wide, life-threatening, anaphylactic shock. Individuals with a disorder of mast cell activation				
27	can experience many such symptoms. $H_2$ receptor antagonists, such as ranitidine, are commonly				
28	prescribed in this population.				
29	A mechanism for the reaction is proposed in the context of ranitidine, as an inverse agonist, causing				
30	upregulation of $H_2$ histamine receptors and raised histamine levels due to enzyme induction. This				
31	effect, following extended and/or high antihistamine dosing, may have implications for other				
32	individuals with a disorder of mast cell activation, such as mastocytosis or mast cell activation				
33	syndrome. There are potential policy and patient guidance implications for primary and secondary				
34	care with respect to cessation of $H_2$ antagonists.				
35					
36	Key words: ranitidine, mast cell activation, histamine, upregulation, anaphylaxis				
37 What is already known					
38	• Ranitidine, H <sub>2</sub> -receptor antagonist (inverse agonist):				
39	- can manage symptoms associated with gastric hyperacidity and mast cell activation				
40	- has caused: anaphylaxis (rare) upon initiation; intragastric hyperacidity on cessation				
41	• Sustained $H_2$ antagonism can: upregulate receptors; alter levels of histamine synthesizing and				
42	metabolizing enzymes				
43	• H <sub>1</sub> /H <sub>2</sub> cross-desensitisation has been reported				

44

#### 45 What this paper adds

- Observed anaphylactoid symptoms on stopping ranitidine (in an individual with mast cell
   activation syndrome)
- 48 A proposed mechanism relating to:
- 49 upregulation of histamine receptors
- 50 raised histamine levels due to altered transmitter turnover
- 51 receptor cross-talk.
- There may be policy implications for cessation of H<sub>2</sub> antagonists
- 53

### 54 Introduction

Anaphylaxis, a type-1 hypersensitivity response, can be a life-threatening event caused by flooding of mast and basophil cell-derived mediators in response to a stimulus. Drug-induced anaphylaxis has increased in frequency with the advent and administration of a widening array of therapeutic agents. Ranitidine, an H<sub>2</sub> receptor antagonist, is one such medication which has been reported, albeit rarely, to cause anaphylaxis upon initiation [1]. Although hyperacidity following cessation of ranitidine has been well-documented, to the best of our knowledge, wider histaminergic symptoms have not.

62 Developed following the pioneering work of Black *et al.* (1972), ranitidine has been widely

63 prescribed since its introduction to the market in 1981 and was a first choice to reduce gastric acid

output in gastro-oesophageal reflux disease, functional dyspepsia, and benign gastric or duodenal

65 ulceration [2]. Although its use has been to a large extent superseded by proton pump inhibitors

66 (PPI), such as lansoprazole and omeprazole, it is still widely prescribed and is also available to

67 purchase in lower strength formulations from UK pharmacies and other retail outlets. Individuals

- 68 with hypermobile Ehlers-Danlos syndrome and/or a disorder of mast cell activation can be
- 69 prescribed ranitidine to manage gastric symptoms.

70 The Ehlers-Danlos syndromes (EDS) are rare heritable disorders of connective tissues. These 71 syndromes have until recently been classified under the Villefranche Nosology, which described six 72 subtypes of the disorder. In March 2017 the International EDS Consortium proposed a revised 73 classification of thirteen EDS subtypes [3]. Hypermobile EDS (hEDS) is the most common of these 74 subtypes with a prevalence of 1-5 per 10,000 individuals. hEDS is diagnosed by satisfying clinical 75 criteria relating to generalised joint hypermobility, family history, and the presence or absence of 76 signs and symptoms of other connective tissue disorders [3]. Functional gastro-intestinal problems 77 are common and individuals can suffer gastric reflux, nausea, abdominal discomfort and altered gut 78 transit times, leading to both constipation and diarrhoea [4,5].

79 Disorders associated with mast cell activation include mastocytosis and the poorly understood mast 80 cell activation syndrome (MCAS, or idiopathic MCAS). Current proposed MCAS diagnostic criteria 81 are: episodic multisystem symptoms consistent with mast cell activation (which can be due to both 82 IgE- and non-IgE-mediated triggers); appropriate response to medication that targets mast cell 83 activation; documented increases in validated systemic markers of mast cell activation during a 84 symptomatic period compared with the patient's baseline values [6]. However, mast cell activation 85 that is associated with another chronic inflammatory disease does not always meet the diagnostic 86 criteria and can be difficult to diagnose [7,8]. In these patients there is commonly a history of 87 multisystem morbidity of an inflammatory or allergic nature and features of inappropriate mast cell 88 activation, but without evidence of mast cell proliferation [9]. It has further been proposed that lack 89 of raised tryptase, where there is evidence of elevated histamine, suggests involvement of basophils, 90 and that gastric signs and symptoms appear to be more associated with raised histamine than 91 tryptase [10,11]. An association between hEDS, MCAS and postural tachycardia syndrome (PoTS) has 92 been identified [12].

93 The biogenic amine histamine is synthesized and stored in "professional" basophils and mast cells
94 and released through exocytosis to play a central role in inflammatory or allergic reactions. Four

95 histamine receptor subtypes have been identified, H<sub>1</sub>, H<sub>2</sub>, H<sub>3</sub> and H<sub>4</sub>; all are G protein-coupled 96 receptors (GPCRs) [13]. Constitutive or spontaneous activity, where a receptor response can be 97 generated in the absence of bound agonist, has been shown for many GPCRs including histamine 98 receptors [14,12]. According to the two-state model for GPCR function, receptors can switch 99 between resting and activated states. Where constitutive activity occurs, a proportion of receptors 100 exists in the active conformation in the absence of bound ligand. Agonists tend to shift the 101 equilibrium towards the active receptor state, while inverse agonists shift it towards the resting 102 state [15,16]. The  $H_2$  receptor ligand ranitidine is known to act as an inverse agonist at the  $H_2$ 103 histamine receptor [17].

Histamine is arguably the most pleiotropic chemical in the human body and its receptors have a
wide distribution. H<sub>1</sub> receptors are located in the central nervous system (CNS), smooth muscle,
sensory nerves, heart, immune and skin cells, among others [13]. Stimulation of these receptors can
give rise to symptoms due to: bronchiolar and gastrointestinal (GI) smooth muscle contraction
(causing bronchospasm and difficulty breathing, and diarrhoea respectively); sensory stimulation of
the epidermis and dermis (causing itch and pain); vasodilation (causing hypotension, flushing and
headache) [16].

H<sub>2</sub> receptors are also widely distributed and found in high concentrations in gastric mucosa, the
uterus, CNS, heart and vasculature, respiratory tract, and cells involved in immune function [13,16].
The majority of histamine receptors in the skin are thought to be H<sub>1</sub>, with around fifteen percent
being H<sub>2</sub> [18]. Stimulation of H<sub>2</sub> receptors promotes hydrochloric acid secretion from gastric parietal
cells and can cause symptoms associated with gastric hyperacidity. H<sub>2</sub> receptor stimulation in the
cardiovascular system increases heart rate and contractility.

H<sub>3</sub> receptors are highly expressed in the CNS and have a wide distribution elsewhere in the body,
including the GI tract, heart, skeletal muscle and sensory nervous system, including in the dermis
[13]. Less is known about the most recently discovered H<sub>4</sub> histamine receptor, although mRNA

expression studies have indicated a wide distribution and particular abundance in cells of the
immune system, including lymphocytes, monocytes, neutrophils, and eosinophils. H<sub>4</sub> expression has
also been demonstrated in the sensory nervous system, skin fibroblasts, GI tract and kidney [13].
Definitive demonstrations of protein and functional expression have, however, yet to be reported
[13].

125 The potentially life-threatening symptoms associated with anaphylaxis are multifaceted and include 126 hypotension, bronchospasm, gastrointestinal symptoms, angio- and laryngeal oedema, cutaneous 127 symptoms and hypothermia [19,20]. These symptoms are induced in susceptible individuals by 128 diverse triggers, including certain foods, insect stings, stress and medication. Such triggers bring 129 about release of the mediators of the pathophysiological effects seen in this serious allergic reaction 130 in which histamine has a central role acting at its receptors located on the affected cells/organs. 131 There is also evidence that histamine influences the activity of a number of inflammatory cell types 132 and is implicated in allergic inflammation via all of the histamine receptors [21], with  $H_3$  and  $H_4$ 133 displaying notable high potency for histamine [13].

134 Case report

Here we report anaphylactoid symptoms in a white British female aged 19 with co-morbidities of
hEDS, MCAS and PoTS, which followed cessation of high-dose ranitidine and culminated in
administration of adrenaline.

Medication in the days preceding the anaphylactoid event were: cetirizine tablets 10mg, one at night; Slow Sodium tablets 600mg, 8 daily; paracetamol tablets 500mg, one or two when required, (not taken in the week prior to the event); ondansetron tablets 4mg, one when required (not taken in the week prior to the event); omeprazole tablets 10mg (not taken in the week prior to the event), two at night; and ranitidine 300mg tablets, one twice daily (dose increased from 300mg to 600mg daily, 5 weeks prior to the event). The patient had been advised to stop gastric acid-altering medication in readiness for a gastroscopy and had gradually reduced the dose of omeprazole over a one week period; dosing had stopped 10 days prior to the anaphylactoid event. In the three days preceding the event ranitidine was reduced as follows: day 1 - morning dose was omitted and 300mg was taken in the evening; day 2 – morning dose was taken and further dosing stopped. The patient became symptomatic from the evening of day 3 onwards, with symptoms worsening from the morning of day 4.

150 The patient had not experienced anaphylaxis before; the only IgE-mediated allergy she had shown

151 previously was to latex. She had identified a number of food intolerances which caused gastric

symptoms, but these symptoms had improved following the addition of H<sub>1</sub> (cetirizine) and increased

153 H<sub>2</sub> (ranitidine) antihistamine medication. She was following a low-FODMAP (fermentable

oligosaccharides, disaccharides, monosaccharides and polyols) diet [22] and low histamine diet and
had not eaten anything different to normal in the days leading up to the event.

#### 156 Symptoms leading to administration of adrenaline

157 On day 3 (described above), the patient experienced abdominal cramps and shivering in the evening 158 and felt cold and dizzy. She woke through the night due to abdominal pain and felt shivery and cold 159 and generally unwell. The abdominal pain continued the following morning and she described 160 feeling shivery, having a running nose and a tight throat, and finding her breakfast hard to swallow. 161 She described looking at her tongue in the mirror because it felt "weird". She had not experienced 162 these symptoms before. Despite symptoms she went to college but continued to feel cold and 163 noticed a mild red blotchy rash on her arms and felt somewhat itchy all over. Her throat became 164 more bothersome and her chest started to feel tight; at this point she sought medical attention.

At the minor injuries unit she was seen immediately. On arrival at 11:07 she was given a 4mg stat dose of oral H<sub>1</sub> antagonist, chlorphenamine. Recorded observations at 11:15 were: temperature 36.6°C; pulse 96 beats/min; respiration rate 15 breaths/min; blood pressure 140/87 mmHg; oxygen saturation 99.8%. At 11:35 observations were: pulse 83 beats/min; respiration rate 20 breaths/min;, blood pressure 143/79 mmHg, oxygen saturation 100%. No flushing, urticaria, stridor or angioedema
were observed. At 11:45 the tightness in her chest and throat increased, face flushed, oxygen
saturation dropped to 92% and she was administered a stat dose of adrenaline (0.5ml, 1:1000) and
oxygen was commenced. Symptoms rapidly abated and she was transferred to the general hospital
for observation. She recovered quickly and fully.

#### 174 Discussion

175 The case report describes the symptoms experienced by a 19 year old female following cessation of 176 the H<sub>2</sub> receptor antagonist ranitidine. The patient had been prescribed ranitidine to manage gastric 177 symptoms associated with mast cell activation and had taken a 600mg daily dose for 5 weeks prior 178 to the event described here, which coincided with withdrawal of the drug. The 600mg daily dose is 179 at the licensed maximum and is consistent with recommended dosing for prophylaxis and healing of 180 NSAID (non-steroidal anti-inflammatory drugs) -induced duodenal and gastric ulcers, and moderate 181 to severe GORD (gastro-oesophageal reflux disease) [23]. A dose of 300mg daily is, however, more 182 commonly seen in practice.

The early symptoms of shivering, stomach cramps, giddiness (or dizziness, as described by the patient), rhinorrhoea and tongue and throat symptoms experienced by the patient are classic symptoms mediated by histamine, acting at its widely-distributed G protein-coupled receptors.

H<sub>1</sub> and H<sub>2</sub> receptors are co-expressed by many cell types at varying densities, whilst H<sub>3</sub> and H<sub>4</sub>
receptors appear to have a more limited distribution [13]. Stimulation of H<sub>1</sub>, H<sub>2</sub> and H<sub>3</sub> receptors has
been implicated in inducing hypothermia in rodents [20, 24, 25], and abdominal pain and diarrhoea
in humans [25]. The patient's subsequent symptoms of chest and throat tightness and flushing are
also those of registered anaphylactic reactions attributed to H<sub>1</sub> and H<sub>2</sub> receptor stimulation [27]; a
contribution from activated H<sub>3</sub> and H<sub>4</sub> receptors cannot be discounted.

192 Fullarton and colleagues [28,29] reported the well-documented rebound nocturnal hyperacidity 193 after abrupt withdrawal of a number of H<sub>2</sub> receptor antagonists, including ranitidine. The authors 194 proposed that the underlying mechanism responsible for this phenomenon could be upregulation of 195 parietal cell H<sub>2</sub> receptors. Since then, the concept of constitutive, or spontaneous, activity of many 196 GPCRs has developed, including histamine receptors, in which a proportion of receptors exist in an 197 active state in the absence of agonist [14]. Although almost all of these studies have been conducted 198 in genetically-manipulated systems [reviewed in 13], it is important to note that spontaneous 199 activity of  $H_3$  receptors has been recorded in a native system [30]. It seems likely that the related  $H_2$ 200 receptor also exhibits this behaviour in vivo.

201 In 1996, using a transfected cell model, Smit et al. demonstrated that a number of H<sub>2</sub> receptor 202 antagonists, including ranitidine and cimetidine, acted as inverse agonists driving the receptor 203 equilibrium towards the resting state. In doing so these ligands inhibit basal, agonist-independent, 204 activity [17]. The authors described an increase in  $H_2$  receptor density following exposure to 205 ranitidine and cimetidine that was both time- and dose-dependent. This upregulation led to 206 increased basal ligand-independent activity which they suggested might underlie tolerance to these 207 drugs and also contribute to the rebound hyperacidity experienced by patients. Jones et al. [31] 208 observed an exaggerated response to a histamine analogue in patients who had been treated for 209 three months with ranitidine at a dose of 150mg at night. They suggested that this observation 210 reflected an increase in receptor number (or upregulation). Upregulation is believed to relate to 211 suppression of H<sub>2</sub> receptor degradation and the recycling of H<sub>2</sub> receptors [32].

Symptoms of rebound hyperacidity have been observed in patients between 24 and 48 hours after the final dose of H<sub>2</sub> antagonist [29,33]. This is consistent with the appearance of the histaminergic symptoms in the case reported here, which began to develop 36 hours from the last dose of ranitidine and became severe at 48 hours. It is tempting to speculate that, in this case, chronic treatment with high dose ranitidine led to H<sub>2</sub> receptor upregulation, giving rise to an increased 217 population of spontaneously active receptors and resulting in H<sub>2</sub> receptor-mediated histaminergic
218 symptoms.

It should be noted that the patient involved in this report had been diagnosed with MCAS, where

histamine. In such a case, the consequences of ranitidine-induced receptor upregulation could

symptoms are experienced as a result of excessive release of pro-inflammatory mediators, including

conceivably be magnified, leading to extreme symptoms upon abrupt cessation of ranitidine dosing.

219

220

221

222

223 An upregulation of H<sub>2</sub> receptors might reasonably account for those symptoms that are obviously 224 mediated by this class of receptor, such as abdominal discomfort. It is less clear how it could account 225 for effects mediated by H<sub>1</sub> (or H<sub>3</sub> or H<sub>4</sub>) receptors. It has recently become apparent, however, that 226 cross-talk exists between co-localized H<sub>1</sub> and H<sub>2</sub> receptors, with heterodimers forming and being co-227 internalized when either receptor is stimulated [34,35]. Once internalized, these receptor dimers 228 may contribute to signalling events and to the overall cellular response. If such events prove to be 229 commonplace, this cross-talk between  $H_1$  and  $H_2$  receptors could explain the appearance of  $H_1$ -230 mediated symptoms, such as rhinorrhoea, that were experienced by this patient.

231 Histamine is synthesized from histidine in a reaction catalysed by histidine decarboxylase (HDC). 232 Monczor and Fernandez [34] described induction of this enzyme by the  $H_2$  receptor antagonist 233 famotidine, resulting in increased levels of histamine, which the authors suggested could contribute 234 to rebound hyperacidity [34]. Such an increase in histamine may be expected to evoke cellular 235 effects mediated by all histamine receptors, and conceivably to an exaggerated response through 236 the up-regulated population of  $H_2$  receptors following antagonist exposure, as seen in this patient. 237 Animal studies have shown that the turnover of histamine varies in different tissues, with resultant 238 differences in histamine half-life (t<sup>1</sup>/<sub>2</sub>) of minutes to several days [36]. This variation in histamine 239 turnover has a number of possible explanations in addition to alterations in local tissue HDC. These 240 include receptor-mediated changes in histamine metabolising enzymes (histamine N-methyl

transferase, diamine oxidase), enzyme polymorphisms [37] and differences in histamine uptake
activities (deranged histamine turnover). It has also been known for many years that in certain
tissues, such as gastric mucosa, H<sub>2</sub> receptor antagonists modulate histamine breakdown by
histamine N-methyltransferase [38]. Differences in turnover of histamine in the various tissues
affected could account for the timing of symptom onset experienced by the patient.

Taken together, these findings offer a plausible explanation for the symptoms experienced by the patient, which were apparently precipitated by withdrawal of the H<sub>2</sub> receptor antagonist ranitidine. It is proposed that upregulation of H<sub>2</sub> receptors and/or increased levels of histamine underlie these effects. Through cross-talk between H<sub>1</sub> and H<sub>2</sub> receptors, activation of H<sub>1</sub> receptors might also contribute to the full gamut of symptoms experienced by the patient. It is postulated that the severity of symptoms here was a consequence of the sustained duration of high-dose ranitidine, followed by its rapid removal, and the patient's disorder of mast cell activation and hEDS.

Patients with a disorder of mast cell activation (and also gastric symptoms associated with hEDS) can be prescribed both H<sub>1</sub> and H<sub>2</sub> antagonists at elevated doses that are above the manufacturer's guidelines for the drug. This patient was prescribed ranitidine at the maximum dosage and cetirizine at the normal recommended dose. If this reaction had been predicted, increasing the dose of H<sub>1</sub> antagonist prior to ranitidine withdrawal might have reduced the adverse symptoms associated with cessation.

Although hypotension is common in anaphylaxis, patients can also display hypertension which may be a stress response [39]. In the half hour leading up to the administration of adrenaline, two raised systolic readings were recorded in this patient. The effect of anxiety on blood pressure and in promoting further mediator release, thereby exacerbating symptoms in the hospital, cannot be ruled out. In addition, antagonising H<sub>2</sub> receptors has been reported to modify the turnover of 5hydroxytryptamine (5-HT) [40], another mediator of anaphylaxis and modulator of mood. Mast cell 5-HT, together with histamine released following intestinal anaphylaxis, can stimulate mesenteric afferents via 5-HT<sub>3</sub> and histamine H<sub>1</sub> (not H<sub>2</sub> or H<sub>3</sub>) receptors. Information regarding intestinal
 immune status can therefore be rapidly relayed to the CNS, and may play a critical role in neural
 reflexes and behavioural responses [41,42].

#### 269 **Conclusions and possible implications for therapy and policy**

The prescribed dose of ranitidine was the maximum recommended daily dose for the drug. Patients referred for gastroscopy are advised to stop taking medications that interfere with gastric acid production; this includes proton pump inhibitors and H<sub>2</sub> receptor antagonists. Advice varies as to when medication should be interrupted and usually recommends cessation one or two weeks before the procedure. There is no recommendation to taper the dose of H<sub>2</sub> antagonists leading to stoppage. Gradual reduction in dose, leading to stoppage, may or may not have been sufficient to avoid or

276 reduce symptoms associated with excess histamine, or enhanced histamine sensitivity, in this 277 patient. As described above, rebound hyperacidity following abrupt cessation of H<sub>2</sub> antagonists is 278 well-documented. Outstanding questions relate to whether the reaction reported here occurred as a 279 consequence of the prior high dose and duration of ranitidine treatment; the abruptness of 280 cessation; the patient's disorder of mast cell activation (and hEDS); or a combination of some or all 281 of these factors. It is proposed that further investigation of widespread histaminergic symptoms in 282 relation to cessation of H<sub>2</sub> antagonists may be of benefit, and in particular amongst this population 283 who may be at increased risk.

#### 284 Nomenclature of Targets and Ligands

Key protein targets and ligands in this article are hyperlinked to corresponding entries in
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to
PHARMACOLOGY [43], and are permanently archived in the Concise Guide to PHARMACOLOGY
2017/18 [44].

289 References

290	1.	Aouam K, Bouida W, Fredj NB, Chaabane A, Boubaker H, Boukef R et al. Severe ranitidine-
291		induced anaphylaxis: a case report and literature review. J Clin Pharm Ther. 2012;37(4):494-
292		496
293	2.	Parsons ME, Ganellin CR. Histamine and its receptors. Br J Pharmacol. 2006;147(Suppl
294		1):S127–S135
295	3.	Malfait F, et al. The 2017 international classification of the Ehlers–Danlos syndromes. Am J
296		Med Genet C. 2017; <b>175</b> (1):8–26
297	4.	Zarate N, Farmer AD, Grahame R, Mohammed SD, Knowles CH, Scott SM et al. Unexplained
298		gastrointestinal symptoms and joint hypermobility: is connective tissue the missing link?
299		Neurogastroenterol Motil. 2010; <b>22</b> (3):232-e78
300	5.	Fikree A, Ghelimsky G, Collins H, Kovacic K, Aziz Q. Gastrointestinal involvement in the
301		Ehlers-Danlos syndrome. Am J Med Genet C Semin Med Genet. 2017;175(1):181-187
302	6.	Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: proposed diagnostic criteria. J
303		Allergy Clin Immunol. 2010; <b>126</b> :1099-1104
304	7.	Valent P. Mast cell activation syndromes: definition and classification. Allergy. 2013;68:417-
305		424
306	8.	Afrin LB, Molderings GJ. A concise, practical guide to diagnostic assessment for mast cell
307		activation disease. World J Hematol. 2014;3(1):1-17
308	9.	Afrin LB, Butterfield JH, Raithel M, Molderings GJ. Often seen, rarely recognized: mast cell
309		activation disease – a guide to diagnosis and therapeutic options. Ann Med. 2016;48(3):190-
310		210
311	10.	Lin RY, Lin Schwartz LB, Curry A, Pesola GR, Knight RJ, Lee H-S, et al. Histamine and tryptase
312		levels in patients with acute allergic reactions: an emergency department-based study. J
313		Allergy Clin Immunol. 2000; <b>106</b> (1):65-71
314	11.	Akin C. Mast cell activation syndromes. J Allergy Clin Immunol. 2017;140(2):349-355

315	12.	Cheung I, Vadas P. A New Disease Cluster: Mast Cell Activation Syndrome, Postural
316		Orthostatic Tachycardia Syndrome, and Ehlers-Danlos Syndrome J Allergy Clin Immunol.
317		<i>suppl.</i> 2015; <b>S 135</b> (2): AB65
318	13.	Panula P, Chazot PL, Cowart M, Gutzmer R, Leurs R, Liu WLS et al. International Union of
319		Basic and Clinical Pharmacology. XCVIII. Histamine Receptors. Pharmacol Rev. 2015;67:601-
320		655
321	14.	Milligan, G. Constitutive activity and inverse agonists of G protein-coupled receptors: A
322		current perspective. <i>Mol Pharmacol</i> .2003; <b>64,</b> 1271-1276.
323	15.	Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory
324		actions and cardiac effects. Clin Exp Allergy. 2002;32:489-498
325	16.	Mahdy AM, Webster NR. Histamine and antihistamines. Anaesthesia and Intensive Care
326		<i>Medicine.</i> 2011; <b>12</b> (7):324-329
327	17.	Smit MJ, Leurs R, Alewijnse AE, Blauw J, Van Nieuw Amerongen GP, Van De Vrede Y et al.
328		Inverse agonism of histamine $H_2$ antagonist accounts for upregulation of spontaneously
329		active histamine H <sub>2</sub> receptors. <i>Proceedings of the National Academy of Sciences USA</i> .
330		1996; <b>93</b> :6802-6807
331	18.	Fedorowicz Z, van Zuuren EJ, Hu N. Histamine H2 receptor antagonists for urticaria (review)
332		Cochrane Collaboration 2012
333	19.	Kemp SF, Lockey RF. Anaphylaxis: A review of causes and mechanisms. J Allergy Clin
334		Immunol. 2002; <b>110</b> (3):341-348
335	20.	Makabe-Kobayashi Y, Hori Y, Adachi T, Ishigaki-Suzuki S, Kikuchi Y, Kagaya Y et al. The control
336		effect of histamine on body temperature and respiratory function in IgE-dependent systemic
337		anaphylaxis. J Allergy Clin Immunol. 2002;110(2):298–303
338	21.	Bachert C. The role of histamine in allergic disease: re-appraisal of its inflammatory
339		potential. <i>Allergy</i> . 2002; <b>57:</b> 287-296

340	22.	Gibson PR, Shepherd SJ. Evidence-based dietary management of functional gastrointestinal
341		symptoms: the FODMAP approach. J Gastroenterol Hepatol.2010;25 (2):252-258
342	23.	Joint Formulary Committee, 2017. British National Formulary 73. London: BMJ Group &
343		Pharmaceutical Press
344	24.	Parolaro D, Patrini G, Massi P, Mainardi P, Giagnoni G, Sala M <i>et al</i> . Histamine as a central
345		modulator of rat intestinal transit. J Pharmacol Exp Ther. April 1989;249(1):324-328
346	25.	Herwig A, Ivanova EA, Lydon H, Barrett S, Steinlechner S, Loudon AS. Histamine H₃ receptor
347		and orexin A expression during daily torpor in the djungarian hamster ( <i>Phodopus sungorus</i> ).
348		J Neuroendocrinol. 2007; <b>19</b> (12):1001-1007
349	26.	Wood JD. Histamine, mast cells, and the enteric nervous system in the irritable bowel
350		syndrome, enteritis, and food allergies. Gut. 2006;55(4):445-447
351	27.	Worm M, Edenharter G, Rueff F, Scherer K, Pfohler C, Mahler V et al. Symptom profile and
352		risk factors of anaphylaxis in Central Europe. Allergy. 2012;67:691-698
353	28.	Fullarton GM, McLauchlan G, Macdonald A, Crean GP, McColl KE. Rebound nocturnal
354		hypersecretion after four weeks treatment with an H <sub>2</sub> receptor antagonist. <i>Gut.</i>
355		1989; <b>30</b> :449-454
356	29.	Fullarton GM, Macdonald AM, McColl KE. Rebound hypersecretion after H <sub>2-</sub> antagonist
357		wthdrawal – a comparative study with nizatidine, ranitidine and famotidine. Aliment
358		Pharmacol Ther. 1991; <b>5</b> (4):391-398
359	30.	Morisset S, Rouleau A, Ligneau X, Gbahou F, Tardivel-Lacombe J, Stark H et al. High
360		constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature
361		<b>408</b>  14 DECEMBER 2000:860-864
362	31.	Jones B, Howden DW, Burget DW, Silletti C, Hunt H. Alteration of $H_2$ receptor sensitivity in
363		duodenal ulcer patients after maintenance treatment with an H <sub>2</sub> receptor antagonist. Gut.
364		1988; <b>29:</b> 890-893

- 365 32. Osawa S, Kajimura M, Yamamoto S, Ibuma M, Mochizuki C, Iwasaki H *et al*. Alteration of
- intracellular histamine H<sub>2</sub> receptor cycling precedes antagonist-induced upregulation. *Am J Physiol Gastrointest Liver Physiol.* 2005;**289**(5):G880-889
- 368 33. Nwokolo CU, Smith JTL, Sawyerr AM, Pounder RE. Rebound intragastric hyperacidity after
- abrupt withdrawal of histamine H<sub>2</sub> receptor blockade. *Gut.* 1991;**32**:1455-1460
- 370 34. Monczor F, Fernandez N. Current knowledge and perspectives on histamine H<sub>1</sub> and H<sub>2</sub>
- 371 receptor pharmacology: functional selectivity, receptor crosstalk and repositioning of classic
- 372 histaminergic ligands. *Mol Pharmacol.* 2016;**90**:640-648
- 373 35. Alonso N, Fernandez N, Notocovich C, Monczor F, Simaan M, Baldi A et al. Cross-
- 374 desensitization and cointernalization of H<sub>1</sub> and H<sub>2</sub> histamine receptors reveal new insights
- 375 into histamine signal integration. *Mol Pharmacol*. 2013;**83**:1087-1098
- 36. Wingren U, Enerbäck L. Turnover of histamine in mucosal and connective tissue mast cells of
  the rat. *Agents and Actions*. 1984;14(3–4):358–360
- 378 37. Peterson J, Raithel M, Schwelberger HG. Characterisation of functional polymorphisms of

the human diamine oxidase gene. *Inflamm Res*. 2005;**54**(1):S58-9

- 380 38. Lorenz W, Thon K, Barth H, Neugebauer E, Reimann HJ, Kusche J. Metabolism and function
- 381 of gastric histamine in health and disease. *J Clin Gastroenterol.* 1983;**5**(1):37-56
- 382 39. Moss J, Fahmy NR, Sunder N, Beaven MA. Hormonal and hemodynamic profile of an
- anaphylactic reaction in man. *Circulation* 1981; **63**:210-213
- 384 40. Skrzydlo-Radomańska B, Pokora J, Kleinrok Z, Radwam P. The effect of stimulation and
- 385 blocking of histamine H<sub>2</sub> receptors on the turnover of the serotonin in different parts of the
- alimentary tract and the brain of the rat. *Agents and Actions*. 1985;**16**(3-4):183-86
- 387 41. Kreis ME, Haupt W, Kirkup AJ, Grundy D. Histamine sensitivity of mesenteric afferent nerves
  388 in the rat jejunum. *Am J Physiol.* 1998;**275**(4 Pt 1):G675-80.

- 42. Jiang W, Kreis ME, Eastwood C, Kirkup AJ, Humphrey PP, Grundy D. 5-HT (3) and histamine H
- 390 (1) receptors mediate afferent nerve sensitivity to intestinal anaphylaxis in rats.

391 *Gastroenterology*. 2000;**119**(5):1267-75.

- 43. Harding SD, Sharman JL, Faccenda E, Southan C, Pawson AJ, Ireland S *et al*. The IUPHAR/BPS
- 393 Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to
- 394 IMMUNOPHARMACOLOGY. *Nucl Acid Res*. 2018;**46**:D1091-106.
- 395 44. Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Marrion NV, Peters JA et al. The
- 396 Concise Guide to PHARMACOLOGY 2017/18: G protein-coupled receptors. Br J
- 397 *Pharmacol.* 2017;**174**:S17–S129.